Intervacc publishes the 2024 Annual Report

Intervacc AB (publ) announces that the company's 2024 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the company's website intervacc.com.

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600

E-mail: [email protected]

The information was submitted for publication, through the agency of the contact person set out above on April 4, 2025 at 08.30 CET.

About Intervacc

Intervacc AB (publ) is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on the proprietary technology platform with fused recombinant proteins. The Intervacc share is listed on Nasdaq First North Growth Market.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: [email protected], Phone: +46 (0)8 – 684 211 10